China & Asia’s Rising Role in Pharma Dealmaking

Session details:

• How China and broader Asia-Pacific innovation ecosystems are reshaping global pharma BD&L pipelines
• Key differences in deal structures, timelines, and risk allocation compared with U.S. and European transactions
• Navigating regulatory, IP, and data governance considerations when partnering across Asian markets
• The evolving role of cross-border licensing, NewCo formations, and regional carve-outs in Asia-driven deals
• Practical lessons from recent successful (and stalled) China–global pharma transactions and what BD teams should do differently going forward